Structure Therapeutics (GPCR) announced positive topline clinical trial results for two oral small molecule candidates for chronic weight management: ACCG-2671 (amylin receptor agonist) and aleniglipron (GLP-1 receptor agonist). The data includes promising efficacy and safety profiles for both programs, supporting their continued development.
Key Details
- ACCG-2671 (Amylin Agonist): Phase 1/2a single ascending dose (SAD) trial showed a single 10mg dose was associated with a 3.3% mean body weight reduction by Day 24. The drug demonstrated a half-life of approximately 6 days, and the next data readout (MAD portion) is expected in the first half of 2027.
- Aleniglipron (GLP-1 Agonist): 72-week results from an open-label extension trial demonstrated continued weight loss of up to 16.2%, with no evidence of a plateau. The trial also confirmed improved gastrointestinal tolerability with a 2.5mg starting dose, with fewer than 5% of participants discontinuing due to adverse events.
- Next Steps: The company has initiated the multiple ascending dose (MAD) portion of the ACCG-2671 trial. Aleniglipron is currently being evaluated in a Phase 3 program, with topline data expected in the second half of 2028.